**2022 FightMND Drug Development Grant – Letter of Intent form (3 pages max.)**

|  |
| --- |
| **Project Title** |
| **Primary Investigator** |
| **Administering Institution** |
| **Estimated budget for each year of funding (AUD):** Year 1 $  Year 2 $  Year 3 $  **TOTAL $** The total budget including indirect costs cannot exceed AUD $1,000,000 (unless additional funding sources are available outside of these grants). FightMND does not provide funding for indirect or overhead costs, or on-costs, of an Administering Institution. |
| **Duration of project** (Years): |
| **Number of subjects to be enrolled** (if applicable): ~  |
| **Number of Australian Clinical Sites** (if applicable): |
| Is the lead candidate a new or a re-purposed therapeutic?  |

|  |  |  |
| --- | --- | --- |
| Does the application include the use of a biomarker(s) to confirm target engagement of the lead compound? | YES [ ]  | NO [ ]  |
| Does the application address the blood-brain-barrier permeability of the lead compound? | YES [ ]  | NO [ ]  |

**Briefly describe any relevant pre-clinical or clinical evidence that supports the study rationale.**

**Project aims.**

**Project Key Words (4 minimum):**

**Briefly describe the study design.**

**Where applicable, list the MND models that will be utilised in the proposal:**

**Indicate how the aims of this project will help translate therapeutics for the treatment of MND/ALS to the clinic.**

**Details of each collaborator involved in the project, including:**

* + - **Name;**
		- **Affiliations; and**
		- **Specific role relevant to project aims.**

Attach a brief CV of the Primary Investigator (2 pages max.) to this letter of intent for consideration.

If invited to submit a full application, where the budget for the overall project exceeds the maximum amount of AUD 1,000,000 awarded by FightMND, the full application will require disclosure of budget details of the entire study, including: the TOTAL funding amount so far secured for the entire study; the approach being made by the applicants to secure the additional funding (if not secured); and the anticipated timeframe to secure the additional funding.